Efficacy and Safety of Etrasimod in Patients with Moderately to Severely Active Isolated Proctitis: Results From the Phase 3 ELEVATE UC Clinical Programme.
Laurent Peyrin-BirouletMarla C DubinskyBruce E SandsJulian PanésStefan SchreiberWalter ReinischBrian G FeaganSilvio DaneseAndres J YarurGeert R D'HaensMartina GoetschKarolina WosikMichael KeatingKrisztina LazinJoseph WuIrene ModestoAoibhinn McDonnellLauren BartolomeSéverine VermeirePublished in: Journal of Crohn's & colitis (2024)
Etrasimod demonstrated significant improvements versus placebo in patients with isolated proctitis, and those with more extensive disease, in most efficacy endpoints at Week 12 and 52.